To explore the effect of palmitoylation on the sorting of EGFR to PM, we first treated two cell lines expressing endogenous EGFR, a triple-negative breast cancer (TNBC) cell line MDA-MB-231, and a non-small cell lung cancer (NSCLC) cell line A54916,17, with 2-bromopalmitate (2-BP), an inhibitor of protein palmitoylation. This evidence concerns the gene EGFR and triple-negative breast carcinoma.